Redeye provides an initial comment on SciBase's Q4 report, where sales came in somewhat above our estimates, while costs were higher than expected. The company continues to position itself for broader adoption through reimbursement, which we believe will be a key catalyst for accelerating sales significantly. We expect initial reimbursement from smaller commercial insurance channels in the near term, with broader public coverage potentially following thereafter.
LÄS MER
